Biogen and Eisai claim further evidence of Aduhelm effect

12 November 2021

Aduhelm (aducanumab), the Alzheimer’s drug from Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523), has not had an easy start to life on the US market.

Following its approval by the US Food and Drug Administration (FDA) in June of this year, there have been doubts expressed over its effectiveness, price tag and whether the FDA was right to grant the approval at all. The US Department of Veterans Affairs dealt Aduhelm a further blow by excluding it from its national formulary in August.

"We believe these new findings can help inform treatment choice"But Biogen and Eisai continue to provide evidence suggesting that the drug can make a difference in Alzheimer’s, a disease where countless drugmakers have failed to develop an effective treatment over the past 30 years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK